AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00725777
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard artemether-lumefantrine treatment
Trial: NCT04148534
Drug: Rocroniom, Non Depolarizing Muscle Relaxant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
Trial: NCT01460563
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline as same dose as MgSO4 as placebo
Trial: NCT00382161
Drug: Fluvastatin-sodium
RxNorm normalized name: Fluvastatin Sodium
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01979380
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, once in the morning
Trial: NCT02561871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
Trial: NCT03802032
Drug: KY jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical KY jelly
Trial: NCT00785863
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo IV and remifentanil infusion
Trial: NCT00785863
Drug: Parecoxib and remifentanil
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib IV and remifentanil infusion
Trial: NCT03887624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
Trial: NCT01066923
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator for daily aspirin therapy
Trial: NCT01066923
Drug: Acute placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator for acute aspirin therapy
Trial: NCT04390958
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1750mg/m2 po bid d1-14
Trial: NCT00824473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01509755
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily injection, under the skin (s.c.) for 12 weeks
Trial: NCT02269904
Drug: Fluorouracil Implants
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
Trial: NCT02269904
Drug: Xelox regimes
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
Trial: NCT01453140
Drug: Cyclophosphamide and Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily.
Trial: NCT01453140
Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off.
Trial: NCT01453140
Drug: Cyclophosphamide and Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1: Cyclophosphamide Day 2: Sirolimus
Trial: NCT01899027
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
Trial: NCT01899027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
Trial: NCT04501276
Drug: ADG116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Trial: NCT04501276
Drug: ADG106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Trial: NCT00756249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vials with solution for IV infusion
Trial: NCT01485094
Drug: GRT6010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given once daily.
Trial: NCT01485094
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily.
Trial: NCT01100658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day for 1 week.
Trial: NCT05032287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT04331210
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
Trial: NCT00839436
Drug: CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03061474
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
Trial: NCT03061474
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03516604
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, identical to PF-04995274 tablet
Trial: NCT03516604
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, identical to citalopram capsule
Trial: NCT04301466
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
Trial: NCT01291511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
Trial: NCT02497924
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
Trial: NCT01246427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Trial: NCT03257813
Drug: PRO-122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Trial: NCT03257813
Drug: Krytantek Ofteno®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Trial: NCT04402957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution
Trial: NCT03445884
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
Trial: NCT02299726
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02795117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02576639
Drug: CNP520
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02576639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to CNP520 was supplied in capsules.
Trial: NCT03615924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day.
Trial: NCT03778099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg of starch and 50 mg of cinnamon powder
Trial: NCT04617652
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
Trial: NCT04201249
Drug: Piroxicam, lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
Trial: NCT00518869
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
Trial: NCT01511172
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin placebo administered orally. 1000 mg daily
Trial: NCT01511172
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
Trial: NCT00047593
Drug: IOP Lowering Medications
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01932450
Drug: antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
Trial: NCT00475319
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT00475319
Drug: 1% OPC-12759 ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT00475319
Drug: 2% OPC-12759 ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT02203630
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
Trial: NCT01184508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily, for 12 weeks
Trial: NCT01184508
Drug: LY2300559
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 milligrams (mg) administered orally, once daily, for 12 weeks
Trial: NCT01122602
Drug: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
Trial: NCT01122602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets
Trial: NCT04810793
Drug: Tetracycline , Furazolidone and Esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
Trial: NCT04810793
Drug: Tetracycline,Furazolidone and Vonoprazan fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
Trial: NCT03684265
Drug: Meloxicam Capsule (Test)
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT03684265
Drug: Meloxicam Tablet (Reference)
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT04820439
Drug: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of HS627 420mg
Trial: NCT04820439
Drug: Perjeta ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of Perjeta ®420mg
Trial: NCT03630224
Drug: Plasmalyte Viaflo
RxNorm normalized name: Plasmalyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
Trial: NCT03721341
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy may be given as indicated.
Trial: NCT03721341
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy may be given as indicated.
Trial: NCT03721341
Drug: Hormones
RxNorm normalized name: Other hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormones may be given as indicated.
Trial: NCT02394535
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01900795
Drug: V117957
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V117957 4.5 mg suspension taken orally after surgery.
Trial: NCT01900795
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg tablets taken orally after surgery.
Trial: NCT01900795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally after surgery.
Trial: NCT03630224
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
Trial: NCT03247543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered once daily
Trial: NCT03247543
Drug: 400mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg SPN-812 was administered once daily and compared to placebo
Trial: NCT02762136
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02762136
Drug: Xiang-sha-liu-jun granules
RxNorm normalized name: Calagel Reformulated Jun 2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
Trial: NCT00751075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Trial: NCT02366351
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 12 weeks
Trial: NCT02366351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 12 weeks
Trial: NCT01653756
Drug: IPI-145, a PI3K Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug
Trial: NCT02537249
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
Trial: NCT00917865
Drug: anti [18F]FACBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
Trial: NCT00833365
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
Trial: NCT00833365
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
Trial: NCT01918644
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04005755
Drug: Maxigesic® IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
Trial: NCT00949845
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03116516
Drug: Temisartan/Amlodipine+Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
Trial: NCT03116516
Drug: YHP1604
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single oral dose of YHP1604 administered in the morning.
Trial: NCT00381108
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets, twice daily.
Trial: NCT00866866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab PO BID
Trial: NCT01227876
Drug: Ster
RxNorm normalized name: Oyster
DrugBank: Oyster (DB10550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone 1% ophthalmic suspension
Trial: NCT03035422
Drug: Lymphocyte injection of prophylactic donor (PDLI)
RxNorm normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II
Trial: NCT00937508
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill without any active medication
Trial: NCT00614679
Drug: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
Trial: NCT01347073
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
Trial: NCT00626340
Drug: MDD diagnosis with both Estrogen and Fluoxetine treatment
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
Trial: NCT01872026
Drug: ASP7991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00626340
Drug: No depression and estrogen treatment
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
Trial: NCT00638534
Drug: Telithromycin (HMR3647)
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03634085
Drug: BDM-2 in Bottle (50 mg - 3600 mg); oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
Trial: NCT01889875
Drug: ALK Grazax 75,000 SQ-T Phleum pratense
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02072213
Drug: Omix Ocas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4mg once a day
Trial: NCT00945282
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
Trial: NCT00945282
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly Active Antiretroviral therapy of the doctor's choice.